Why we treat orphan diseases
United Therapeutics was created in 1996 to develop a treatment for our founder's youngest daughter Jenesis, who had been diagnosed with a life-threatening orphan disease. That year we began funding early academic research but soon realized it would take many years for these products to reach the market. We were fortunate to acquire a compound from a large pharmaceutical company that had no plans for further development of the product.
In the years since, we have commercialized 4 therapies, all beginning with that initial compound.
As we looked to expand, with a focus on rare, life-threatening diseases, pediatric oncology was a natural fit for our company.
Our commitment to orphan diseases
We believe that even the smallest patient populations deserve access to treatment options, and we intend to continue that mission. We feel obliged and honored to provide treatment options for patient populations with rare diseases, and we are privileged to work in partnership with the pediatric neuroblastoma community. This opportunity has given our mission new depth as our commitment to those with orphan diseases continues to broaden.